Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report)’s share price fell 7.2% during mid-day trading on Friday . The stock traded as low as $4.30 and last traded at $4.37. 27,346 shares changed hands during trading, a decline of 57% from the average session volume of 63,041 shares. The stock had previously closed at $4.71.
Portage Biotech Trading Down 7.2 %
The stock’s 50 day moving average is $4.72 and its 200 day moving average is $4.70. The firm has a market cap of $4.58 million, a price-to-earnings ratio of -0.10 and a beta of 1.33.
Institutional Trading of Portage Biotech
An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC purchased a new stake in shares of Portage Biotech Inc. (NASDAQ:PRTG – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned about 1.04% of Portage Biotech as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.36% of the company’s stock.
About Portage Biotech
Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
Read More
- Five stocks we like better than Portage Biotech
- Canada Bond Market Holiday: How to Invest and Trade
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Short Selling – The Pros and Cons
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Investing in Travel Stocks Benefits
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.